Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465296 · ClinicalTrials.gov registry record · Phase 3
Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS
A Phase 3 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00465296: Clinical Trial Phase 3 study, sponsored by Medstar Health Research Institute.
NCT00465296 is a Phase 3 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 200 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00465296, a Phase 3 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with metabolic syndrome. The secondary parameter for evaluation of efficacy is binary restenosis. The tertiary objective will be to assess the effect of rosiglitazone on major cardiac events (MACE; death, MI, CABG, and target vessel revascularization). The occurrence of in-stent restenosis for patients with metabolic syndrome who receive a DES in a non-target lesion will be assessed angiographically at 9 months.
Interventions
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Why NCT00465296 stopped before completion
NCT00465296 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone is the first listed.
NCT00465296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00465296 about?
NCT00465296 is a clinical study titled "Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS". The primary objective of this clinical trial is to assess the efficacy of rosiglitazone on bare metal stent (BMS) in-stent restenosis measured as late lumen loss in patients with metabolic syndrome. The secondary parameter for evaluation of efficacy is binary restenosis. The tertiary objective wil...
What is the current status of trial NCT00465296?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00465296?
The interventions under investigation include: rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00465296?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00465296's enrollment target sits among peer trials
200 1353rd of 2000 higher than 613 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia